BioNTech CBO Outlines Infectious Disease Ambitions
German mRNA-focused biotech BioNTech is branching out from its immuno-oncology focus to explore the potential of its platforms in infectious diseases. Speaking at the sidelines of BIO-Europe 2018, Sean Marett, BioNTech’s CBO and CCO, reveals how deals signed in the second half of 2018, with Pfizer to create a new type of flu vaccine and Penn University to deliver up to 10 IND-ready infectious disease-targeted assets, will underpin the development of a second major pillar for the company.
You may also be interested in...
BioNTech gets an €80m boost to its reserves as Sanofi takes equity stake as partners extend 2015 deal and advance an mRNA-based cancer immunotherapy into clinic against multiple solid tumors
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.